Technology giant Hewlett-Packard (HPQ) has demonstrated an impressive performance so far this year. The stock jumped impressively by 16% year to date as investors were positive by the turnaround of the PC giant. The focus on the cloud and 3D printing by Hewlett-Packard has helped the company strengthen its business and stop the revenue decline to some extent in a weak PC sales environment.
The Way Forward
The PC market weakness had badly affected HP. There were declining computer sales owing to the gaining momentum for mobile devices such as smartphones and tablets. However, HP should be able to witness an increase in computer sales going forward due to an increase in demand from businesses after Microsoft (MSFT) stopped supporting Windows XP in April. This has forced business consumers to upgrade to the latest Windows software and buy new machines for employees.
HP is focusing on product innovation to add more value to its products. HP has launched its new converged system portfolio, which is a group of integrated IT systems that use HP server, storage and networking technology built for key workloads such as virtualizations, big data and hosted desktops. These solutions are designed to deliver a total systems experience to simplify information technology and enable clients to go from order to operations in just 20 days.
Top 5 Paper Companies To Buy Right Now: PetSmart Inc(PETM)
PetSmart, Inc., together with its subsidiaries, operates as a specialty retailer of products, services, and solutions for pets in the United States, Puerto Rico, and Canada. The company offers consumables, such as pet food, treats, and litter; and hardgoods, which include pet supplies and other goods comprising collars, leashes, health care supplies, grooming and beauty aids, toys, apparel, and pet beds and carriers, as well as aquariums and habitats, accessories, d�or, and filters for fish, birds, reptiles, and small pets. It also provides fresh-water fish, small birds, reptiles, and small pets; and pet services, such as grooming, including precision cuts, baths, nail trimming and grinding, and teeth brushing, as well as training, boarding, and day camp services. In addition, the company operates PetsHotels that offer boarding for dogs and cats; provides personalized pet care, an on-call veterinarian, temperature controlled rooms and suites, daily specialty treats and p lay time, and day camp services for dogs; and operates veterinary hospitals, which offer services comprising routine examinations and vaccinations, dental care, a pharmacy, and surgical procedures. As of January 29, 2012, it operated 1,232 retail stores; 192 PetsHotels; 791 veterinary hospitals under the trade name of Banfield, The Pet Hospital; and 8 hospitals operated through other third parties in Canada. The company also offers its products through an e-commerce and community site, PetSmart.com. PetSmart, Inc. was founded in 1986 and is based in Phoenix, Arizona.
Advisors' Opinion:- [By Jeremy Bowman]
What:�Shares of�PetSmart,� (NASDAQ: PETM ) were looking clever today, climbing as much as 15%, and finishing up 12.5% after JANA partners disclosed a stake in the pet-supply retailer.�
- [By Lauren Pollock]
Pet-products retailer PetSmart Inc.(PETM) boosted its quarterly dividend by 18% while announcing a plan to repurchase $535 million in shares.
RDA Microelectronics Inc.(RDA) has received a takeover proposal from Shanghai Pudong Science & Technology Investment Co. valuing the Chinese semiconductor company at $745 million. PDSTI, a state-owned investment company, offered to buy RDA for $15.50 an American depositary share, a 12% premium to RDA’s closing price Thursday. RDA shares were halted premarket ahead of the news.
Best Information Technology Stocks To Watch For 2014: Moody's Corporation(MCO)
Moody?s Corporation, through its subsidiaries, provides credit ratings; credit and economic related research, data, and analytical tools; risk management software; and quantitative credit risk measures, credit portfolio management solutions, training, and financial credentialing and certification services worldwide. Its Moody?s Investors Service segment publishes credit ratings on debt obligations, including various corporate and governmental obligations, structured finance securities, and commercial paper programs, as well as the entities that issue such obligations in markets worldwide. This segment provides ratings in approximately 110 countries. Its ratings are disseminated via press releases to the public through print and electronic media, including the Internet and real-time information systems, which is used by securities traders and investors. As of December 31, 2010 this segment had ratings relationships with approximately 11,000 corporate issuers and approximate ly 22,000 public finance issuers. It also rated and monitored ratings on approximately 102,000 structured finance obligations. The company?s Moody?s Analytics segment develops products and services that support the risk management activities of institutional participants in financial markets. It also distributes investor-oriented research and data, including research on debt issuers, industry studies, and commentary on topical events developed by MIS as part of its rating process. In addition, this segment provides economic research, and credit data and analytical tools, such as quantitative credit risk scores; economic and regulatory capital risk management software and implementation services; and quantitative credit risk measures, credit portfolio management solutions, training, and financial credentialing and certification services. It serves approximately 4,100 institutions in approximately 115 countries. The company was founded in 1900 and is headquartered in New York, New York.
Advisors' Opinion:- [By Laura Brodbeck]
Earnings reports expected on Friday include:
Procter & Gamble Company (NYSE: PG) is expected to report first quarter EPS of $1.06 on revenue of $21.09 billion, compared to last year�� EPS of $1.06 on revenue of $20.74 billion. United Parcel Services (NYSE: UPS) is expected to report EPS of $1.15 on revenue of $13.60 billion, compared to last year�� EPS of $1.06 on revenue of $13.07 billion. Moody�� Corporation (NYSE: MCO) is expected to report third quarter EPS of $0.81 on revenue of $715.85 million, compared to last year�� EPS 0f $0.75 on revenue of $688.50 million billion. Lear Corporation (NYSE: LEA) is expected to report third quarter EPS of $1.33 on revenue of $3.84 billion, compared to last year�� EPS 0f $1.29 on revenue of $3.54 billion.Economics
- [By Associated Press]
"So far the ECB's actions have not translated into lower lending rates for businesses and households, failing to boost activity," said Anna Zabrodzka, economist at Moody's (NYSE: MCO ) Analytics.
- [By Donald van Deventer]
The legacy credit ratings (those reported by credit rating agencies like McGraw-Hill (MHFI) unit Standard & Poor's and Moody's (MCO)) for Goldman Sachs Group have changed only three times during the decade.
- [By Rich Smith]
Alamy For years -- ever since the Great Recession ended -- pundits have been pontificating about a strange trend in corporate America. Despite earning record profits, and having the ability to borrow cash easily, companies were refusing to spend. Like Scrooge in his office, they were raking in profits ... and then sitting on them, refusing to put the money to work to grow the American economy. Or so the story went. But was it true? it true? It turns out that this real story is a bit more complicated; and you'll be surprised where a lot of that cash came from ... and what it needs to be spent on. A Kernel of Truth Every complex tale grows from a kernel of truth, of course, and this one actually grows out of two such kernels. It's true that American corporations are fabulously profitable today. According to the Department of Commerce, profit margins at U.S. companies in 2013 were regularly hitting levels of 9.3 percentage points -- more than 57 percent higher than average over the past 60 years. Also true is that these profits, in turn, yielded a lot of cash for the corporations earning them. From 2006 through mid-2013, total cash reserves at U.S. nonfinancial companies (i.e., everything but banks) nearly doubled, rising from $820 billion to $1.48 trillion, an 81 percent increase. Credit ratings company Moody's (MCO) recently estimated that cash levels at the end of 2013 probably hit $1.5 trillion.
Best Information Technology Stocks To Watch For 2014: Canada Bread Company Ltd (CBY)
Canada Bread Company, Limited is a manufacturer and marketer of flour-based products in its various markets, including fresh bread in Canada, frozen partially baked bread in the United States and Canada, specialty bakery products, including fresh pasta and sauces, sweet goods and snack cakes in Canada, and bagels, croissants and other specialty baked goods in the United Kingdom. It operates in two segments: Fresh Bakery business includes pantry breads, rolls, flatbreads, artisan breads, sweet goods and snack cakes sold under a number of brands, including Dempster��, Villaggio, POM, Bon Matin and Ben��, and Frozen Bakery segment consists of frozen par-baked bakery products sold in North America and the United Kingdom bakery business, which specializes in bagels, croissants, and specialty breads. In November 2013, the Company clearanced and closed the sale of Olivieri Foods, to Ebro Foods SA. Advisors' Opinion:- [By Gerrit De Vynck]
The Toronto-based food producer, which owns 90 percent of Canada Bread Co. (CBY), said in October it would explore options for the stake, including a possible sale as it divests assets to focus on its meat business. With several suitors evaluating the company, a sale is looking more likely, said one of the people, who asked not to be named because the talks are private. Maple Leaf hired Centerview Partners LLC and Royal Bank of Canada to look for buyers, the people said.
Best Information Technology Stocks To Watch For 2014: Osiris Therapeutics Inc.(OSIR)
Osiris Therapeutics, Inc., a stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. It operates in two business segments, Therapeutics and Biosurgery. The Therapeutics segment focuses on developing biologic stem cell drug candidates from a readily available and non-controversial source, adult bone marrow. The Biosurgery segment works to harness the ability of cells and novel constructs to promote the body's natural healing. This segment focuses on developing biologic products for use in surgical procedures. The company?s lead biologic drug candidate is Prochymal, which is in phase 2 and 3 clinical trails for various indications, including acute graft versus host disease (GvHD), Crohn's disease, acute myocardial infarction, type 1 diabetes, pulmonary disease, and gastrointestinal injury resulting from radiation exposure. Its biologic drug candidates also include Chondrogen, a preparation of adult mesenchymal stem cells that is in phase 2 clinical trials for osteoarthritis and cartilage protection. The company has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen in various countries except in the United States and Canada. It also has a partnership with Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
Advisors' Opinion:- [By Maxx Chatsko]
Additionally, stem cell therapies have remained elusive as the industry's ultimate Holy Grail. Osiris (NASDAQ: OSIR ) received Canadian approval for the world's first stem cell drug, Prochymal, for children battling acute graft-versus-host disease, or GvHD, last year. The approval meant more symbolically than to the bottom line, but it definitely put the potential of stem cells front and center for investors.
Best Information Technology Stocks To Watch For 2014: Orexigen Therapeutics Inc.(OREX)
Orexigen Therapeutics, Inc., a development stage company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed phase III clinical trials; and Empatic that has completed phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; and naltrexone is a treatment for alcohol and opioid addiction. The company?s Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide is for the adjunctive treatment of partial seizures, a form of epilepsy. The company has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave. Orexigen Therapeutics, Inc. was founded in 2002 and is based in La Jolla, California.
Advisors' Opinion:- [By Jake L'Ecuyer]
Shares of Orexigen Therapeutics (NASDAQ: OREX) got a boost, shooting up 9.64 percent to $6.23 after the company announced successful results of the interim analysis of the Light Study.
Best Information Technology Stocks To Watch For 2014: BIOLASE Inc (BIOL)
BIOLASE, Inc., formerly BIOLASE Technology, Inc., incorporated in 1987, is a medical technology company that develops, manufactures and markets lasers, and markets and distributes dental imaging equipment and other related products designed for applications and procedures in dentistry and medicine. The Company's dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications in a minimally invasive manner. The Company also manufactures and sells disposable products and accessories for its laser systems. The Company's Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed. The Company also markets flexible fibers and hands pieces. For the Company's ezlase system, the Company sells tooth whitening gel kits. In April 2012, it purchased 159 Waterlase MD Turbo laser systems from Henry Schein, Inc.
The Company's Waterlase Dentistry consists of two product lines Waterlase systems and Diode systems. In July 2011, the Company introduced the Biolase DaVinci Imaging line of imaging products, which enabled the Company to offer digital diagnostic solutions to complement the minimally invasive dental treatment solutions offered by its Waterlase and Diode dental systems. The Company added the distribution of the NewTom cone beam computed tomography (CBCT), to its imaging product line. The integration of the Company's laser products with imaging offers dental professionals the Total Technology Solution, which provides imaging capabilities for early diagnosis and minimally invasive treatment with its Waterlase iPlus and iLase laser technologies.
The Company's all-tissueWaterlase dental laser systems consist of the Waterlase iPlus, the Waterlase MD Turbo, and the Waterlase MDX 300 and 450, both introduced in February 2012. Each of these systems is designed around the Company's yttrium scandi! um gallium garnet (YSGG) laser technology that refers to the laser crystal used in the Waterlase system, which contains the elements erbium, chromium and yttrium, scandium, gallium and garnet. This crystal laser produces energy with specific absorption and tissue interaction characteristics optimized for dental applications. HydroPhotonics refers to the interaction of YSGG lasers with water to produce energy to cut tissue. It is minimally invasive and can cut hard tissue, such as bone and teeth, and soft tissue, such as gums or skin, without the heat, vibration, or pressure associated with traditional dental treatments. By eliminating heat, vibration, and pressure, the Company's Waterlase systems eliminate the need for anesthesia.
The Waterlase systems incorporate an ergonomic handpiece and a control panel located on the front of the system with precise preset functionality to control the mix of laser energy, air, and water, as well as the pulse rate. The Waterlase iPlus incorporates the iLase wireless diode laser that can be utilized for unexpected soft-tissue cases in an adjacent treatment room, controlling bleeding, and temporary pain relief.
The Company's Diode laser systems in dentistry consist of the ezlase and iLase, semiconductor diode lasers to perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and temporary pain relief. The Company's ezlase system serves the markets of general, cosmetic, orthodontic and hygienic procedures. It features a pulse mode, ComfortPulse, which allows the tissue to cool between pulses and reduces the need for anesthesia for many common procedures. Other features include a wireless foot pedal control, disposable single-use tips, color touch screen activation with up to fifteen procedure based pre-sets, a whitening hand piece, a rechargeable battery pack, and a wall mount.
The Company's imaging systems include the Company's design and distribution of extra-oral and intra-oral dental digital imaging devices. The Co! mpany's e! xpansion into digital imaging systems enables the Company to offer diagnostic solutions to complement the minimally invasive dental treatment solutions offered by the Company's Waterlase and Diode dental systems. The Company provides both high-precision intuitive diagnosis and treatment planning solutions. The Company's Biolase DaVinci Imaging systems include the D3D, a three dimensional (3D) CBCT, and portable digital x-ray and intra-oral camera devices.
The NewTom VGi is a small-footprint CBCT system that offers medical grade imaging technology. In addition to producing up to image resolution with medical grade rotating anode technology, SafeBeam technology automatically adjusts radiation dosage. The Company's Medical systems include the Diolase 10 Diode Laser. As of December 31, 2011, the Company has sold approximately 8,700 Waterlase systems, including over 4,700 Waterlase MD and iPlus systems, and more than 19,000 laser systems in total in over 60 countries. As of decembe31, 2011, the Company�� other products under development address ophthalmology, dermatology, orthopedics, podiatry, and other medical and consumer markets.
The Company competes with Lares Dental Research, Fotona d.d., KaVo Dental GmbH, Lambda SpA, J Morita Manufacturing Corp., Syneron Medical Ltd, Deka Laser Technologies, Inc. Ivoclar Vivadent, Inc., Dentsply, Inc., Royal Philips Electronics and Sirona Dental Systems, Inc.
Advisors' Opinion:- [By Anna Prior]
Biolase Inc.(BIOL) swung to a fourth quarter loss as the dental lasers manufacturer and distributor’s revenue fell, and the company said it was exploring strategic alternatives. Revenue fell short of analysts’ expectations. Shares dropped 7.7% to $2.98 in light premarket trading.
- [By Roberto Pedone]
One health care player that's starting to trend within range of triggering a major breakout trade is Biolase (BIOL), which is a medical technology company that develops, manufactures and markets laser systems for dental and medical applications. This stock is off to a decent start in 2013, with shares up 12%.
If you take a look at the chart for Biolase, you'll notice that this stock has been trending sideways and consolidating for the last two months, with shares moving between $1.64 on the downside and $2.24 on the upside. Shares of BIOL have now started to spike higher right off its 200-day moving average of $1.87 a share. That spike is quickly pushing shares of BIOL within range of triggering a major breakout trade above the upper-end of its recent sideways trading chart pattern.
Traders should now look for long-biased trades in BIOL if it manages to break out above some near-term overhead resistance levels at $2.15 to $2.24 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 627,655 shares. If that breakout triggers soon, then BIOL will set up to re-test or possibly take out its next major overhead resistance levels at $3.50 to $4 a share.
Traders can look to buy BIOL off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $1.85 to $1.80 a share. One can also buy BIOL off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By James E. Brumley]
Looking for a quick, high-odds bullish trade? Then look for further than BIOLASE Inc. (NASDAQ:BIOL). This small medical equipment company has had nothing less than a miserable 2013, falling from a peak above $6.00 in April to a multi-year low of $1.16 on Wednesday. But, the size and scope of that plunge from BIOL has also dropped all the tell-tale hints that a rebound is nigh.
No comments:
Post a Comment